Clinical trial · no report yet · Phase 3
NIVOPOSTOP
A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck
- NCT03576417 ↗
- Active not recruiting
- Groupe Oncologie Radiotherapie Tete et Cou
- 89 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 50 | |
| YouTube | 21 | |
| Podcasts | 16 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Cisplatin; Nivolumab; RT
- Arms
- RT+ cisplatin · Active comparator
- RT+ cisplatin + nivolumab · Experimental
- Enrollment
- 680
- Primary outcomes
- Disease free survival
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou with For Drug Consulting, Eurofins
- Start
- Oct 10, 2018
- Primary completion
- Aug 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03576417 · updated Oct 2, 2026
Publications
linked from the registry- Bourhis J, Auperin A, Borel C, Lefebvre G, Racadot S, Geoffrois L, Sun XS, Saada E, Cirauqui B, Rutkowski T, Henry S, Modesto A, Johnson A, Chapet S, Calderon B, Sire C, Malard O, Bainaud M, Da Silva Motta A, Thureau S, Pointreau Y, Blanchard P, Buiret G, Bozec L, Lopez S, Vanbockstael J, Bosset M, Greilsamer C, Daste A, Bruna A, N'Guyen F, Plana M, Iruarrizaga E, Temam S, Even C, Ruiz EP, Bert M, Karamouza E, Thariat J, Kazmierska J, Psyrri A, Mesia R, Tao Y. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial. Lancet. 2026 Jan 24;407(10526):363-374. doi: 10.1016/S0140-6736(25)01850-1. Epub 2025 Dec 22. PubMed 41448222